Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to set category-based product coverage and apply deferred price cuts for the price maintenance premium (PMP) for the first time in…
To read the full story
Related Article
- MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
- Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
REGULATORY
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
- LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
- LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…